The United States Food and Drug Administration and Noninferiority Margins in Clinical Trials of Antimicrobial Agents
Open Access
- 15 March 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (6) , 879-881
- https://doi.org/10.1086/339072
Abstract
In summary, one should select a delta for a clinical trial that allows a high degree of certainty that the drug is better than placebo and ensures that any poteKeywords
This publication has 1 reference indexed in Scilit:
- The United States Food and Drug Administration and the End of AntibioticsClinical Infectious Diseases, 2002